WHO Coronavirus (COVID-19) Dashboard (WHO, accessed 22 February 2023); https://covid19.who.int/

Cui, J., Li, F. & Shi, Z. L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 17, 181–192 (2019).

Article  CAS  PubMed  Google Scholar 

Swerdlow, D. L. & Finelli, L. Preparation for possible sustained transmission of 2019 novel coronavirus: lessons from previous epidemics. JAMA 323, 1129–1130 (2020).

Article  CAS  PubMed  Google Scholar 

The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Wkly 2, 113–122 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu, Z. & McGoogan, J. M. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 323, 1239–1242 (2020).

Article  CAS  PubMed  Google Scholar 

Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J. & Prescott, H. C. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19): a review. JAMA 324, 782–793 (2020).

Article  CAS  PubMed  Google Scholar 

Clinical Spectrum of SARS-CoV-2 Infection (NIH, accessed 25 January 2023); https://go.nature.com/3LTfZhQ

Halpin, S. J. et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J. Med. Virol. 93, 1013–1022 (2020).

Article  PubMed  Google Scholar 

Huang, C. et al. 6-Month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 397, 220–232 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stokes, E. K. et al. Coronavirus Disease 2019 case surveillance—United States, January 22–May 30, 2020. MMWR Morb. Mortal. Wkly Rep. 69, 759–765 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fried, M. W. et al. Patient characteristics and outcomes of 11,721 patients with COVID19 hospitalized across the United States. Clin. Infect. Dis. 72, e558–e565 (2020).

Article  Google Scholar 

Garg, S. et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed Coronavirus Disease 2019—COVID-NET, 14 States, March 1–30, 2020. MMWR Morb. Mortal. Wkly Rep. 69, 458–464 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Golestaneh, L. et al. The association of race and COVID-19 mortality. eClinicalMedicine 25, 100455 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Brandén, M. et al. Residential context and COVID-19 mortality among adults aged 70 years and older in Stockholm: a population-based, observational study using individual-level data. Lancet Healthy Longev. 1, e80–e88 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Saloner, B., Parish, K., Ward, J. A., DiLaura, G. & Dolovich, S. COVID-19 cases and deaths in federal and state prisons. JAMA 324, 602–603 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yi, S. H. et al. Characterization of COVID-19 in assisted living facilities—39 states, October 2020. MMWR Morb. Mortal. Wkly Rep. 69, 1730–1735 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coronavirus Disease (COVID-19): Vaccines (WHO, accessed 15 December 2022); https://go.nature.com/40jSwuN

Kaplon, H. & Reichert, J. M. Antibodies to watch in 2021. MAbs 13, 1860476 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19 (US FDA, 9 November 2020); https://go.nature.com/3nq8aGr2020

Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19 (US FDA, 21 November 2020); https://go.nature.com/3JMqFME

Almagro, J. C., Mellado-Sanchez, G., Pedraza-Escalona, M. & Perez-Tapia, S. M. Evolution of anti-SARS-CoV-2 therapeutic antibodies. Int. J. Mol. Sci. 23, 9763 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

COVID-19 Monoclonal Antibodies (Centers for Medicare & Medicaid Services, accessed 21 February 2023); https://www.cms.gov/monoclonal

Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment (Pfizer, 22 December 2021); https://go.nature.com/3KdyjBk

Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19 (MSD, 23 December 2021); https://go.nature.com/3TQLfA3

Alsuliman, T., Alasadi, L., Alkharat, B., Srour, M. & Alrstom, A. A review of potential treatments to date in COVID-19 patients according to the stage of the disease. Curr. Res. Transl. Med 68, 93–104 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S.C. & Di Napoli, R. Features, Evaluation and Treatment Coronavirus (COVID-19). In: StatPearls [Internet]. (Treasure Island (FL): StatPearls Publishing; 2023).

Jin, Y. et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 12, 372 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Siddiqi, H. K. & Mehra, M. R. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J. Heart Lung Transpl. 39, 405–407 (2020).

Article  Google Scholar 

Gaitonde, D. Y., Moore, F. C. & Morgan, M. K. Influenza: diagnosis and treatment. Am. Fam. Physician 100, 751–758 (2019).

PubMed  Google Scholar 

Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab (Eli Lilly and Company, 2022); https://go.nature.com/3zaRpBF

Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of REGEN-COV (Casirivimab and Imdevimab) (Regeneron, 2022); https://go.nature.com/3FXcvHA

Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N. Engl. J. Med. 386, 1397–1408 (2022).

Article  CAS  PubMed  Google Scholar 

Jayk Bernal, A. et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N. Engl. J. Med. 386, 509–520 (2022).

Article  PubMed  Google Scholar 

Petty, L. A. & Malani, P. N. Oral antiviral medications for COVID-19. JAMA 327, 2464 (2022).

Article  CAS  PubMed  Google Scholar 

Merck and Ridgeback’s Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World (MSD, 4 November 2020); https://go.nature.com/40G4i2c

Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study (Pfizer, 5 November 2021); https://go.nature.com/40lf2mT

Bellon, M. et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load kinetics in symptomatic children, adolescents, and adults. Clin. Infect. Dis. 73, e1384–e1386 (2021).

Article  CAS  PubMed  Google Scholar 

Vetter, P. et al. Daily viral kinetics and innate and adaptive immune response assessment in COVID-19: a case series. mSphere 5, e00827-20 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Kissler, S. M. et al. Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated persons. N. Engl. J. Med. 385, 2489–2491 (2021).

Article  PubMed  Google Scholar 

Deo, R. et al. Symptom and viral rebound in untreated SARS-CoV-2 infection. Ann. Intern. Med. 176, 348–354 (2023).

Article  PubMed  Google Scholar 

Datta, S. D., Talwar, A. & Lee, J. T. A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: illness beyond acute infection and public health implications. JAMA 324, 2251–2252 (2020).

Article  CAS  PubMed  Google Scholar 

Nalbandian, A. et al. Post-acute COVID-19 syndrome. Nat. Med. 27, 601–615 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rawson, T. M. et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin. Infect. Dis. 71, 2459–2468 (2020).

CAS  PubMed  Google Scholar 

Venditto, V. J. et al. Immunomodulatory effects of azithromycin revisited: potential applications to COVID-19. Front. Immunol. 12, 574425 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yao, X. et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. 71, 732–739 (2020).

Article  CAS  PubMed  Google Scholar 

Andreani, J. et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Micro. Pathog. 145, 104228 (2020).

Article  CAS  Google Scholar 

Cavalcanti, A. B. et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N. Engl. J. Med. 383, 2041–2052 (2020).

Article  CAS  PubMed  Google Scholar 

Frontera, J. A. et al. Treatment with zinc is associated with reduced in-hospital mortality among COVID-19 patients: a multi-center cohort study. Preprint at Res Sq. https://doi.org/10.21203/rs.3.rs-94509/v1 (2020).

Ni, Y. N. et al. The effect of high-flow nasal cannula in reducing the mortality and the rate of endotracheal intubation when used before mechanical ventilation compared with conventional oxygen therapy and noninvasive positive pressure ventilation. A systematic review and meta-analysis. Am. J. Emerg. Med. 36, 226–233 (2018).

Article  PubMed